Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. eis

EIS SIGNED

An innovative, effective and minimally-invasive retinal cell therapy combined with a new injection system for treatment of retinal degenerative diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EIS project word cloud

Explore the words cloud of the EIS project. It provides you a very rough idea of what is the project "EIS" about.

utilizing    pigmentosa    multiple    ga    degeneration    safe    drafted    dr    initiated    approximately    market    injection    clinical    innovative    amd    lasting    excellent    patients    minimally    severe    chain    reduces    transplantation    everads    plan    obtain    causes    combination    longer    marrow    injections    goto    matrix    office    mscs    billion    degenerative    treatments    invasive    treat    ivt    hbm    treatment    macular    drug    subretinal    perform    geographic    performed    area    effect    device    people    leaving    standard    opportunity    optimal    eis    organ    rp    blindness    ensures    fact    pressure    escalation    atrophy    age    worldwide    innovation    platform    dosage    cataract    impairments    ivts    adult    human    close    feasibility    risk    trials    suffering    registered    supply    strategy    techniques    disease    visual    consequence    retina    ocular    life    retinal    intravitreal    regard    80    license    iop    debilitating    glaucoma    stromal    choroidal    bone    daily    setting    mesenchymal    blood    first    cell    photoreceptor    marketing    vessels    therapeutic    million    retinitis    cells   

Project "EIS" data sheet

The following table provides information about the project.

Coordinator		 EVERADS THERAPY LTD 

Organization address
address: 27 HABARZEL STREET MIGDALEI ORR BUILDING A 5TH FLO
city: TEL AVIV
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERADS THERAPY LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Retinal degenerative disease is a debilitating condition with a major impact on daily life. This includes Geographic Atrophy(GA) - as a consequence of age-related macular degeneration (AMD) - and advanced Retinitis Pigmentosa (RP) - all characterized by photoreceptor loss. In fact, they are the main causes of registered blindness. In this regard, there are no currently effective treatments for patients suffering from GA a and RP, leaving approximately 2.6 million people across Europe and over 5 million worldwide with the risk of developing severe visual impairments. Standard techniques to treat GA and DR, including Intravitreal Injections (IVTs) and subretinal transplantation present major problems associated with them. Everads developed a treatment for macular and retinal degeneration, utilizing the innovative Everads Injection System (EIS), a minimally invasive platform for optimal injection of Adult Bone Marrow Mesenchymal Stromal Cells (hBM-MSCs). Unique treatment approach allows simple, office-based safe transplantation of hBM-MSCs in the matrix between the choroidal blood vessels, providing excellent distribution very close to the target organ (retina) and long-term therapeutic effects, targeting multi-billion market opportunity. The Everads treatment is safe, minimally-invasive, can be performed in an office setting and ensures 80% drug distribution in the retinal area, aiming for longer lasting effect of drug. It also reduces the risk of side effects like increased Intra Ocular Pressure (IOP), glaucoma, cataract typical of IVT injections. During the feasibility assessment, a goto market strategy and a supply chain will be established, and further development plan will be drafted. During the phase 2 of innovation project, Everads will perform further product development and cell distribution and dosage escalation activities. Multiple first in human clinical trials will be initiated to obtain marketing license as a drug-device combination product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More